Fecal DNA Testing Compared with Conventional Colorectal Cancer Screening Methods: A Decision Analysis

Gastroenterology

Volumn 126, Issue 5, 2004, Pages 1270-1279

  Song, Kenneth ^a   Fendrick, A Mark ^b,c   Ladabaum, Uri ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COLON POLYP; COLONOSCOPY; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; FECES ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; SCREENING TEST; SENSITIVITY ANALYSIS;

EID: 2142648692     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.02.016     Document Type: Article

References (67)

1. Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin 2003;53:44-55.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
3. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:132-141.
4. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:96-104.
5. Eddy DM. Screening for colorectal cancer. Ann Intern Med 1990; 113:373-384.
6. Lieberman DA. Cost-effectiveness model for colon cancer screening. Gastroenterology 1995;109:1781-1790.
7. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000;284:1954-1961.
8. Sonnenberg A, Delco F, Inadomi J. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000; 133:573-584.
9. Wagner JL, Tunis S, Brown M, Ching A, Almeida R. Cost-effectiveness of colorectal cancer screening in average risk adults. In: Young G, Rozen P, Levin B, eds. Prevention and early detection of colorectal cancer. Philadelphia: Saunders, 1996:321-356.
10. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, Van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
11. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001;135:769-781.
12. Vijan S, Hwang EW, Hofer TP, Hayward RA. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 2001;111:593-601.
13. Khandker RK, Dulski JD, Kilpatrick JB, Ellis RP, Mitchell JB, Baine WB. A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care 2000;16:799-810.
14. Colorectal cancer test use among persons aged ≥ 50 years-United States, 2001. MMWR Morb Mortal Wkly Rep 2003;52: 193-196.
15. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890.
16. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
17. Ladabaum U, Scheiman JM, Fendrick AM. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med 2003;114: 546-554.
18. Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, Ross ME. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003;3:47-53.
19. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-1227.
20. Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, Hibi K, Goodman SN, D'Allessio M, Paty P, Hamilton SR, Sidransky D, Barany F, Levin B, Shuber A, Kinzler KW, Vogelstein B, Jen J. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-865.
21. Fenlon HM, Nunes DP, Schroy PC III, Barish MA, Clarke PD, Ferrucci JT. A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps. N Engl J Med 1999;341: 1496-1503.
22. Yee J, Akerkar GA, Hung RK, Steinauer-Gebauer AM, Wall SD, McQuaid KR. Colorectal neoplasia: performance characteristics of CT colonography for detection in 300 patients. Radiology 2001;219:685-692.
23. Johnson CD, Toledano AY, Herman BA, Dachman AH, McFarland EG, Barish MA, Brink JA, Emst RD, Fletcher JG, Halvorsen RA Jr, Hara AK, Hopper KD, Koehler RE, Lu DS, Macari M, Maccarty RL, Miller FH, Morrin M, Paulson EK, Yee J, Zalis M. Computerized tomographic colonography: performance evaluation in a retrospective multicenter setting. Gastroenterology 2003;125:688-695.
24. Johnson CD, Harmsen WS, Wilson LA, Maccarty RL, Welch TJ, Ilstrup DM, Ahlquist DA. Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps. Gastroenterology 2003;125:311-319.
25. Pickhardt PJ, Choi JR, Hwang I, Butler JA, Puckett ML, Hildebrandt HA, Wong RK, Nugent PA, Mysliwiec PA, Schindler WR. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003;349:2191-2200.
26. Ransohoff DF. Challenges and opportunities in evaluating diagnostic tests. J Clin Epidemiol 2002;55:1178-1182.
27. Ransohoff DF. Cancer. Developing molecular biomarkers for cancer. Science 2003;299:1679-1680.
28. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003;124:544-560.
29. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003;53:27-43.
30. Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Waye JD, Hall D, Hamlin JA, Schapiro M, O'Brien MJ, Sternberg SS, Gottlieb LS, The National Polyp Study Work Group. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. N Engl J Med 2000;342:1766-1772.
31. Clark JC, Collan Y, Eide TJ, Esteve J, Ewen S, Gibbs NM, Jensen OM, Koskela E, MacLennan R, Simpson JG, Stalsberg H, Zaridze DG. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer 1985;36: 179-186.
32. Vatn MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 1982;49:819-825.
33. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982;23:835-342.
34. Arminski TC, McLean MD. Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon Rectum 1964;7:249-261.
35. Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM. Adenomatous lesions of the large bowel: an autopsy survey. Cancer 1979;43:1847-1857.
36. Morson BC. The evolution of colorectal carcinoma. Clin Radiol 1984;35:425-431.
37. Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2000;95:3053-3063.
38. Bond JH. Clinical evidence for the adenoma-carcinoma sequence, and the management of patients with colorectal adenomas. Semin Gastrointest Dis 2000;11:176-184.
39. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK. SEER Cancer Statistics Review, 1973-1994. NIH Pub. No. 97-2789. Bethesda, MD: National Cancer Institute, 1997:17-166.
40. Life Tables. Vital Statistics of the United States. Preprint of Volume II, Mortality, part A, section 6. Hyattsville, MD: National Center for Health Statistics, 1998.
41. Brand RE, Shuber AP, Laken SJ, Young CM, Urbanowski J. Reliability of a stool DNA mutation specific assay for colorectal cancer. Gastroenterology 2002;122:A479.
42. Syngal S, Chung D, Willet C, Schoetz D, Schroy P, Stoffel E, Jagadeesh D, Morel K, Ross M. The loss of stool DNA mutation abnormalities in colorectal neoplasia after treatment. Gastroenterology 2003;124:A5.
43. Exact Sciences Corporation Press Release, October 11, 2003. PreGen-Plus four times more sensitive than FOBT in Exact Sciences' multi-center study. Available at: http://www.exactsciences.com. Accessed January 8, 2004.
44. Diller W. Exact Sciences' Moment. IN VIVO: The Business & Medicine Report, July 1, 2003:39.
45. Direct Laboratory Services, Inc. Available at: http://www. directlabs.com/testtypes.php. Accessed January 8, 2004.
46. Hardison D. Eradicating cancer through early detection, In CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference 2003, New York, NY, April 30, 2003.
47. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, Ackroyd F, Shike M, Kurtz RC, Hornsby-Lewis L, Gerdes H, Stewart ET, and the National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-1981.
48. The DRG Handbook: Comparative Clinical and Financial Standards. Baltimore, MD: HCIA, Inc. and Emst & Young LLP, 1997.
49. Eddy DM, Nugent FW, Eddy JF, Coller J, Gilbertsen V, Gottlieb LS, Rice R, Sherlock P, Winawer S. Screening for colorectal cancer in a high-risk population. Results of a mathematical model. Gastroenterology 1987;92:682-692.
50. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87:417-426.
51. Fireman BH, Quesenberry CP, Somkin CP, Jacobson AS, Baer D, West D, Potosky AL, Brown ML. Cost of care for cancer in a health maintenance organization. Health Care Finance Rev 1997;18: 51-76.
52. Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999;37:1249-1259.
53. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-481.
54. Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J 1993;148:927-929.
55. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD. Five hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15:369-390.
56. Bureau of Labor Statistics 2003. U.S. Department of Labor. Available at: http://www.bls.gov/cpi/home.htm. Accessed June 1, 2003.
57. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press, 1996:214-235.
58. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-657.
59. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-1607.
60. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-1477.
61. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-1471.
62. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002;50:29-32.
63. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-1371.
64. Schroy PC, Heeren TC. A comparative study of patient perceptions and screening preferences for stool-based DNA testing (SBDNA), fecal occult blood testing (FOBT) or colonoscopy (CS). (abstr) Gastroenterology 2003;124:A-77.
65. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-1641.
66. Rex DK, Lieberman DA. Feasibility of colonoscopy screening: discussion of issues and recommendations regarding implementation. Gastrointest Endosc 2001;54:662-667.
67. Vijan S, Inadomi J, Fendrick AM, Hofer TP, Hayward RA. The impact of colorectal cancer screening recommendations on colonoscopy demand. (abstr) J Gen Intern Med 2002;17:141.